A significant proportion of patients with prostate cancer who are treated with brachytherapy develop gross hematuria years later, report researchers in BJU International. The findings come from a study of 20-year data collected for 2,454 men, aged a mean of 67 years, who received transperineal permanent prostate interstitial brachytherapy. Led by Michael Leapman from the Icahn School of Medicine at Mount Sinai, the team found that 218 (8.9 percent) of the men developed hematuria, over a mean period of 5.9 years, with 628 individual hematuria events identified. Learn more